Stockreport

Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of ATX-559 and Chief Scientific Officer Transition [Yahoo! Finance]

Fulcrum Therapeutics, Inc.  (FULC) 
Last fulcrum therapeutics, inc. earnings: 3/5 07:00 am Check Earnings Report
PDF Second program targeting KIF18A anticipated to enter the clinic in 1H 2025, treating patients with chromosomally instable tumors Seasoned research leader Serena Silve [Read more]